About: Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature
Creator	Baron, David Ba, Aly, Besma Blodget, Emily Hashemi, Areio Kouyoumjian, Sarkis Musa, Arif Pendi, Kasim Stevens, Susan Warbasse, Elizabeth Yousif, Jenna
source	Medline; PMC
abstract	In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting a systematic search of 18 clinical trial registries and three large scientific databases, we identified 86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (κ = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100–200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials are expected to be completed between April 2020–2023. Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population.
has issue date	2020-05-20(xsd:dateTime)
bibo:doi	10.5811/westjem.2020.5.47658
bibo:pmid	32726230
has license	cc-by
sha1sum (hex)	71c8a1e18ce8e334828e23a9a4556ffa0ae29fb5
schema:url	https://doi.org/10.5811/westjem.2020.5.47658
resource representing a document's title	Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature
has PubMed Central identifier	PMC7390571
has PubMed identifier	32726230
schema:publication	West J Emerg Med
resource representing a document's body	covid:71c8a1e18ce8e334828e23a9a4556ffa0ae29fb5#body_text
is schema:about of	named entity 'Remdesivir' named entity 'remdesivir' named entity 'coronavirus outbreak' named entity 'coronavirus disease' named entity 'remdesivir' named entity 'GS-5734' named entity 'inclusion-exclusion' named entity 'metaanalysis' named entity 'intravenous' named entity 'randomized controlled trials' named entity 'adverse events' named entity 'May 2020' named entity 'remdesivir' named entity 'Embase' named entity 'treatment protocol' named entity 'standard of care' named entity 'viruses' named entity 'adverse effects' named entity 'adverse events' named entity 'SARS-CoV-2' named entity 'remdesivir' named entity 'Phase 3 trials' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'United States' named entity 'COVID' named entity 'COVID-19' named entity 'systematic review' named entity 'GS-5734' named entity 'systematic review' named entity 'anti-viral' named entity 'Remdesivir' named entity 'Systematic Review' named entity 'coronavirus' named entity 'global pandemic' named entity 'coronaviruses' named entity 'remdesivir' named entity 'anti-viral' named entity 'oxygen saturation' named entity 'European Union' named entity 'remdesivir' named entity 'maintenance dose' named entity 'viral RNA' named entity 'remdesivir' named entity 'natural reservoir' named entity 'COVID-19' named entity 'remdesivir' named entity 'adverse events' named entity 'Phase 3 clinical trials' named entity 'remdesivir' named entity 'infection' named entity 'diarrhea' named entity 'liver cancer' named entity 'remdesivir' named entity 'coronavirus infections' named entity 'remdesivir' named entity 'pharmacological' named entity 'adverse events' named entity 'SARS-CoV-2' named entity 'oxygen saturation' named entity 'body aches' named entity 'small molecule' named entity 'PubMed' named entity 'March 11' named entity 'Zaire' named entity 'Filoviridae' named entity 'high-quality studies' named entity 'IV infusion' named entity 'adverse reactions' named entity 'milligram' named entity 'patient outcomes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software